Universal, off-the-shelf cell therapy
Allocetra™ is an innovative immunotherapy that is being developed to reprogram macrophages,
which were negatively reprogrammed by certain diseases out of their homeostatic state.
Healthy
Mononuclear cells collected
from healthy donors
Cells modification
Modified through a proprietary
process to express “eat me”
signal (PtdSer) on their surface,
while maintaining an intact membrane
Patient
Triggering engulfment into
macrophages via binding to BAI,
TIM4, and stabilin 2, annexin V
Activated macrophage
Homeostatic macrophage
Clinical focus
Our clinical development programs focus on treating solid tumors, sepsis
and COVID-19. Our most advanced product candidate, Allocetra™ was developed
for the reprogramming of diseased macrophages in patients with sepsis
or COVID-19, and has demonstrated positive safety, tolerability and efficacy
in several clinical trials. We plan on initiating clinical trials of Allocetra™
in solid cancer patients during 2021.
Extensive pre-clinical data
Rich pipeline of registration studies targeting conditional marketing approval
3 primary indications
2010 | iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-kB dependent blockade,
Gil Amarilyo, Dror Mevorach, et al., European Journal of Immunology
